Response to ‘Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest’

We thank Farkhad Manapov and Chukwuka Eze [1] for their interest in our phase III trial of etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small-cell lung cancer [2]. We have addressed here, and hope to clarify, a few points that they raised in their letter.